Literature DB >> 31846803

ROS and GSH-responsive S-nitrosoglutathione functionalized polymeric nanoparticles to overcome multidrug resistance in cancer.

Wen Wu1, Min Chen2, Tingrong Luo2, Ying Fan2, Jinqiang Zhang2, Yan Zhang2, Qianyu Zhang2, Anne Sapin-Minet3, Caroline Gaucher3, Xuefeng Xia4.   

Abstract

Multidrug resistance of cancer cells is one of the major obstacle for chemotherapeutic efficiency. Nitric oxide (NO) has raised the potential to overcome multidrug resistance (MDR) with low side effects. Herein, we report a reactive oxygen species (ROS) and glutathione (GSH) responsive nanoparticle for the delivery of NO prodrug such as S-nitrosoglutathione (GSNO), which was chemically conjugated to an amphiphilic block copolymer. The GSNO functionalized nanoparticles show high NO loading capacity, good stability and sustained NO release with specific GSH activated NO-releasing kinetics. Such GSNO functionalized nanoparticles delivered doxorubicin (DOX) in a ROS triggered manner and increased the intracellular accumulation of DOX. However, in normal healthy cells, showing physiological concentrations of ROS, these nanoparticles presented good biocompatibility. The present work indicated that these multifunctional nanoparticles can serve as effective co-delivery platforms of NO and DOX to selectively kill chemo-resistant cancer cells through increasing chemo-sensitivity. STATEMENT OF SIGNIFICANCE: In this work, we constructed nitric oxide donor (S-nitrosoglutathione, GSNO) functionalized amphiphilic copolymer (PEG-PPS-GSNO) to deliver doxorubicin (DOX). The developed PEG-PPS-GSNO@DOX nanoparticles presented high NO capacity, ROS triggered DOX release and GSH triggered NO release. Thus NO reversed the chemo-resistance in HepG2/ADR cells increasing intrcellular accumulation of DOX. Furthermore, these PEG-PPS-GSNO@DOX nanoparticles exhibited biocompatibility to healthy cells and toxicity to cancer cells, due to elevated ROS.
Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glutathione-responsive; Multidrug resistance of cancer; Nitric oxide; Reactive oxygen species-responsive; S-nitrosoglutathione

Mesh:

Substances:

Year:  2019        PMID: 31846803     DOI: 10.1016/j.actbio.2019.12.016

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  13 in total

Review 1.  Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.

Authors:  Jihoon Kim; Susan N Thomas
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 2.  Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Authors:  Sruthi Sritharan; Sampurna Guha; Snoopy Hazarika; Nageswaran Sivalingam
Journal:  Apoptosis       Date:  2022-06-18       Impact factor: 5.561

Review 3.  Recent advances in anti-multidrug resistance for nano-drug delivery system.

Authors:  Changduo Wang; Fashun Li; Tianao Zhang; Min Yu; Yong Sun
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 4.  Nano Encapsulated Curcumin: And Its Potential for Biomedical Applications.

Authors:  Yan Chen; Yao Lu; Robert J Lee; Guangya Xiang
Journal:  Int J Nanomedicine       Date:  2020-05-01

5.  A GSH/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy.

Authors:  Yang Yang; Quanfeng Zhao; Zhe Peng; Yunjiang Zhou; Miao-Miao Niu; Lin Chen
Journal:  Front Pharmacol       Date:  2022-01-14       Impact factor: 5.810

6.  System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma.

Authors:  Jun Hui Xu; Yong Jun Guan; Zhen Dong Qiu; Xin Zhang; Liu Liu Zi; Yu Zhou; Chen Chen; Jia Yu; Yi Chao Zhang; Wei Xing Wang
Journal:  Oxid Med Cell Longev       Date:  2021-11-08       Impact factor: 6.543

7.  Dual-Sensitive Gold-Nanocubes Platform with Synergistic Immunotherapy for Inducing Immune Cycle Using NIR-Mediated PTT/NO/IDO.

Authors:  Hsin-Yi Tsao; Hung-Wei Cheng; Chia-Chi Kuo; San-Yuan Chen
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-25

Review 8.  Recent Progress of Novel Nanotechnology Challenging the Multidrug Resistance of Cancer.

Authors:  Chengyuan Zhang; Xuemei Zhou; Hanyi Zhang; Xuanliang Han; Baijun Li; Ran Yang; Xing Zhou
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

Review 9.  H2S- and NO-releasing gasotransmitter platform: A crosstalk signaling pathway in the treatment of acute kidney injury.

Authors:  Joana Claudio Pieretti; Carolina Victoria Cruz Junho; Marcela Sorelli Carneiro-Ramos; Amedea Barozzi Seabra
Journal:  Pharmacol Res       Date:  2020-08-14       Impact factor: 7.658

Review 10.  Nanoformulations to Enhance the Bioavailability and Physiological Functions of Polyphenols.

Authors:  Bingyan Yang; Yixin Dong; Fei Wang; Yu Zhang
Journal:  Molecules       Date:  2020-10-10       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.